Schedule 13D ownership disclosure

THERAVANCE BIOPHARMA INC

Security class unavailable · CUSIP: G8807B106

Event date: 2021-11-08

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
9,644,807
Percent of class
13.1000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001387131-22-001550
Form type
SC 13D/A
Filer
GSK plc
CIK
CIK 1131399
Filed
Feb 10, 2022
Reporting period
Nov 08, 2021
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub